EP3126390

CELLECTIS
Application Number
EP15713513A
Filing Date
Apr 2, 2015
Status
Granted And Under Opposition
Sep 13, 2019
Grant Date
Oct 16, 2019
External Links
Slate, Register

Biblio Summary

The patent EP3126390B1 was granted on Oct 16, 2019 by Cellectis The patent is currently Granted And Under Opposition.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJul 14, 2020ADMISSIBLE

The table below shows the patents of Cellectis that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2997141Cd19 Specific Chimeric Antigen Receptor And Uses ThereofOct 12, 20221
EP3116902Method For Generating T-Cells Compatible For Allogenic TransplantationJan 1, 20204
EP3189073Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer ImmunotherapyDec 25, 20191